Systemic melanoma therapy at the end of life: A single institutional retrospective study in Japan

Systemic melanoma therapy at the end of life: A single institutional retrospective study in Japan

Bibliographic Details
Main Authors:	Ayumi Yoto, MD, Kanade Shimada, MD, Sumiko Takatsuka, MD, Tatsuya Takenouchi, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	JAAD International
Subjects:	BRAF/MEK inhibitors drug treatment end of life immune checkpoint inhibitors melanoma terminal stage
Online Access:	http://www.sciencedirect.com/science/article/pii/S266632872200147X

Similar Items

A Dramatic Response to Second-Line Nivolumab and Ipilimumab in BRAF-V600-Mutated Metastatic Melanoma
by: Dahlia Fedele, et al.
Published: (2024-01-01)

Systemic Therapy of Metastatic Melanoma: On the Road to Cure
by: Julian Steininger, et al.
Published: (2021-03-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

Treatment of Advanced Melanoma: Past, Present and Future
by: Taku Fujimura, et al.
Published: (2020-09-01)

Clinical research progress in the treatment of BRAF V600 mutation-positive advanced melanoma
by: JIANG Jianyun, YING Hongmei
Published: (2022-05-01)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)

Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report
by: Bartoušková Marie, et al.
Published: (2020-08-01)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma
by: Ernesto Rossi, et al.
Published: (2023-01-01)

Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland
by: Ramon Staeger, et al.
Published: (2024-02-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Maximilian Haist, et al.
Published: (2022-04-01)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
by: Thomas Jung, et al.
Published: (2021-09-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy
by: Lauretta Levati, et al.
Published: (2022-07-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options
by: Darina Kohoutova, et al.
Published: (2021-02-01)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
by: Nakul Dar, et al.
Published: (2023-08-01)

Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data
by: Sophie H. A. E. Derks, et al.
Published: (2023-02-01)

Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapy
by: Francisco Meraz-Torres, et al.
Published: (2024-01-01)

BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
by: Mattia Garutti, et al.
Published: (2022-12-01)

Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis
by: Jonathan N. Priantti, et al.
Published: (2023-07-01)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
by: Sandra Huynh, et al.
Published: (2020-06-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
by: I. V. Samoylenko, et al.
Published: (2017-11-01)

MEK inhibition and immune responses in advanced melanoma
by: Reinhard Dummer, et al.
Published: (2017-08-01)

The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
by: Silvia Mezi, et al.
Published: (2023-09-01)

The Use of ctDNA for <i>BRAF</i> Mutation Testing in Routine Clinical Practice in Patients with Advanced Melanoma
by: Paweł Sobczuk, et al.
Published: (2022-02-01)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
by: Emmanuelle M. Ruiz, et al.
Published: (2023-05-01)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
by: Tomer Meirson, et al.
Published: (2020-06-01)

Oral Adverse Events Associated with BRAF and MEK Inhibitors in Melanoma Treatment: A Narrative Literature Review
by: Michele Basilicata, et al.
Published: (2024-01-01)

Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma
by: Neel M. Fofaria, et al.
Published: (2017-11-01)

Systemic therapy for Asian patients with advanced BRAF V600‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (B‐CHECK‐RWD study)
by: Kenjiro Namikawa, et al.
Published: (2023-09-01)

Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance
by: William Wagstaff, et al.
Published: (2022-11-01)

Tubulointerstitial Nephritis in an Advanced Melanoma Patient Treated with Encorafenib plus Binimetinib Combination Therapy
by: Yumi Kambayashi, et al.
Published: (2022-05-01)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
by: Francesco Spagnolo, et al.
Published: (2021-05-01)

MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors
by: Maria Letizia Motti, et al.
Published: (2020-06-01)

Adjuvant treatments in melanoma
by: Luka Simetić, et al.
Published: (2021-01-01)

Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors
by: Aya Nishizawa, et al.
Published: (2024-03-01)

Targeted Therapy in Melanoma and Mechanisms of Resistance
by: Anna M. Czarnecka, et al.
Published: (2020-06-01)

The therapeutic potential of targeting minimal residual disease in melanoma
by: Riyaben P Patel, et al.
Published: (2023-03-01)

“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
by: Mattia Garutti, et al.
Published: (2020-07-01)

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
by: Alexander Schulz, et al.
Published: (2022-10-01)